Table 4-3: Results with screening agents for contact allergy to fragrance ingredients reported since 1999 in patients patch tested for suspected allergic contact dermatitis in Europe: Fragrance Mix “I” (see Table 4-1). If not given in the publication, the confidence interval (CI) was calculated from the absolute numbers by the SCCS (§). - Figures and Tables

Table 4-3: Results with screening agents for contact allergy to fragrance ingredients reported since 1999 in patients patch tested for suspected allergic contact dermatitis in Europe: Fragrance Mix “I” (see Table 4-1). If not given in the publication, the confidence interval (CI) was calculated from the absolute numbers by the SCCS (^§).
Country (Ref.)	Population	Year(s)	No. tested	Crude % positive (95% CI)
Sweden (38)	Consecutive patients	2000	3790	6.9
Hungary (39)		1998-1999	3604	8.2 (7.3–9.1)^§
Czech Republic (40)		1997-2001	12058	5.8 (5.4–6.2)^§
Ljubljana, Slovenia (41)	Consecutive patients	1989-1998	6129	5.9 (5.3–6.5)^§
Germany (42)	Consecutive IVDK patients	1996-2002	59298	11.3 (11.0–11.5)^§
Germany (43)	Consecutive IVDK patients	2005-2008	36961	7.3 (7.0–7.6)^§
Vienna, Austria (16)	Consecutive patients of one clinic	1997-2000	2660	9.1 (8.1–10.3)^§
Groningen, Netherlands (44)	Patients (fragrance allergy suspected)	04/2005-06/2007	295	5.8 (3.4–9.1)^§
The Netherlands (45)	Consecutive patients	09/1998-04/1999	1825	10.6 (9.2–12.1)
The Netherlands (46)	Patients (cosmetic allergy suspected)	1994-1998	757	14.8 (12.3–17.5)^§
Leuven, Belgium (47)	Consecutive patients	1990-2005	10128	9.1 (8.6–9.7)^§
Coimbra, Portugal (48)	Consecutive patients	07/1989-06/1999	2600	10.9 (9.7–12.2)^§
Spain (49)	Consecutive patients	10/2005-06/2008	1253	4.5 (3.4–5.8)^§
Sheffield, UK (50)	Consecutive patients	1994-1995	744	11.4 (9.2–13.9)^§
St. John’s, London, UK (51)	Consecutive patients	1980-2004	34072	7.7 (7.4–8.0)^§
Copenhagen, Denmark (52)	Consecutive patients	1985-2007	16173	7.2 (6.8–7.6)^§
ESSCA (53)	Consecutive patients	2002-2003	9663	7.1 (6.6–7.6)^§
ESSCA (54)	Consecutive patients	2004	9941	7.6 (7.1–8.2)^§
ESSCA (55)	Consecutive patients	2005-2006	18542	7.0 (6.6–7.4)^§